AOD-9604 Peptide: Structure, Research Applications, and What the Science Says in 2026

AOD-9604 is a synthetic peptide fragment derived from the C-terminus of human growth hormone (hGH residues 177-191), engineered specifically to isolate lipolytic activity from the full hGH molecule. Researchers and institutions studying metabolic regulation, adipose tissue biology, and lipid metabolism have turned to this compound because it targets fat-related signaling pathways without the anabolic or glycemic effects associated with full-length growth hormone. PeptideValidation.com supplies AOD-9604 as a 2 mg lyophilized powder, formulated for consistent handling and controlled analytical work in qualified laboratory settings. This guide covers everything a researcher needs to know, from molecular background to study design considerations.

Contents

• What Is AOD-9604?
• Molecular Structure and Mechanism
• Key Research Findings on Metabolic Effects
• How AOD-9604 Differs from Full-Length hGH
• Laboratory Handling and Storage Protocols
• AOD-9604 vs. Related Peptide Fragments: A Comparison
• Research Design Considerations
• Regulatory and Compliance Context
• Comparison
• Frequently asked questions
• Sources

What Is AOD-9604?

AOD-9604 (Advanced Obesity Drug) is a synthetic peptide fragment corresponding to amino acid residues 177-191 of human growth hormone. It was designed to replicate the lipolytic (fat-metabolizing) properties of hGH while eliminating anabolic and insulin-sensitizing activity, making it a selective tool in metabolic research.

The name 'AOD-9604' stands for Advanced Obesity Drug, a label that reflects the compound's origins in obesity pharmacology research during the late 1990s and early 2000s. Scientists at Monash University in Australia first isolated this C-terminal fragment and demonstrated that a 15-amino-acid sequence from hGH could drive fat breakdown independently of the rest of the molecule.

The peptide spans residues 177 through 191 of the full 191-amino-acid growth hormone sequence. This region contains the structural elements responsible for interacting with adipocyte receptors involved in lipid mobilization. Crucially, it does not contain the N-terminal region that binds the GH receptor and triggers anabolic signaling or IGF-1 release.

For research purposes, this selectivity is the key attribute. A laboratory investigating lipid metabolism can introduce AOD-9604 into an experimental system without simultaneously activating the broader hormonal cascades that full hGH triggers. That makes results cleaner and interpretation more straightforward.

PeptideValidation.com provides this compound specifically for qualified researchers, laboratories, and institutions conducting analytical, metabolic, or peptide-related studies. The product is supplied as a 2 mg lyophilized powder, a format that supports precise dosing, stable long-term storage, and reproducible experimental conditions. It is strictly for research use only and is not intended for human or veterinary application.

Molecular Structure and Mechanism

AOD-9604 is a 15-amino-acid peptide (Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly) with a molecular weight of approximately 1817 Da. A disulfide bridge between Cys-residues at positions 7 and 15 stabilizes its secondary structure, which is essential for receptor binding activity.

The primary sequence of AOD-9604 reads: Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly. That 15-residue chain folds into a conformation stabilized by an intramolecular disulfide bond between the two cysteine residues. This bond is not incidental. Disrupt it and lipolytic activity drops sharply, which tells researchers that three-dimensional shape, not just sequence, drives function here.

The molecular weight comes in at roughly 1817 daltons. That places it firmly in the low-molecular-weight peptide category, which has practical implications: it dissolves readily in aqueous buffers, passes through common HPLC columns without unusual retention behavior, and can be lyophilized efficiently without significant structural degradation.

At the mechanistic level, the current research model proposes that AOD-9604 interacts with beta-3 adrenergic receptors on adipocytes. Activation of this pathway stimulates adenylyl cyclase, raises intracellular cAMP, and activates hormone-sensitive lipase, the enzyme that catalyzes triglyceride hydrolysis inside fat cells. The released fatty acids then enter systemic circulation for oxidation.

What the peptide does NOT do is equally important for experimental design. It does not bind the classical GH receptor complex that initiates JAK2-STAT5 signaling. It shows no measurable affinity for the IGF-1 receptor. Multiple in vitro assays have confirmed it does not alter glucose uptake or insulin receptor phosphorylation at physiologically relevant concentrations. Researchers working in metabolic disease models find this separation of function particularly useful when they need to isolate fat-oxidation variables from glucose-handling variables.

The disulfide bond also means that reducing agents in assay buffers, such as DTT or beta-mercaptoethanol, will deactivate the peptide. Analytical teams should account for this when designing buffer systems for cell-based or biochemical assays.

Key Research Findings on Metabolic Effects

Preclinical studies in rodent models show AOD-9604 reduces body fat mass by 50% in obese subjects compared to controls over a 19-day period, with no significant change in lean body mass, blood glucose, or insulin levels. These findings position it as a selective lipolytic agent in metabolic research models.

The foundational animal work on AOD-9604 was published in the late 1990s and early 2000s. Rodent studies using diet-induced and genetic obesity models showed consistent reductions in adipose tissue mass. One frequently cited protocol observed a roughly 50% reduction in body fat over 19 days of treatment in obese mice, with lean body mass remaining essentially unchanged. Control animals receiving saline showed no equivalent change.

Researchers also found that the peptide raised resting metabolic rate in treated animals, suggesting an effect on thermogenesis in addition to direct lipolysis. Some studies pointed to increased fat oxidation in brown adipose tissue, which is a distinct mechanism from simple triglyceride hydrolysis in white adipose tissue. Whether these effects are additive or sequential remains an open research question as of 2026.

A phase IIb clinical trial conducted in the mid-2000s under the sponsor Metabolic Pharmaceuticals tested AOD-9604 in overweight human subjects. The trial enrolled several hundred participants and found the compound was well tolerated over 12 weeks. However, the trial did not demonstrate statistically significant weight loss compared to placebo at the primary endpoint, which led the sponsor to halt further pharmaceutical development of the compound as a standalone drug.

For researchers, the clinical trial data is informative rather than disqualifying. The mechanistic in vitro and preclinical evidence remains strong and reproducible. Current academic interest has shifted toward understanding AOD-9604's potential role in lipid signaling pathways, its interaction with adipokine secretion, and whether combination approaches in animal models produce different outcomes than the compound in isolation.

Studies examining cartilage repair have also appeared in the literature, noting that the peptide may influence chondrocyte metabolism. This line of inquiry is separate from the metabolic/lipolytic work and represents a secondary area of interest for musculoskeletal researchers.

How AOD-9604 Differs from Full-Length hGH

Unlike full-length human growth hormone, AOD-9604 does not stimulate IGF-1 production, does not activate JAK2-STAT5 signaling, and does not alter glucose or insulin levels. It retains only the lipolytic region of the hGH molecule, making it a targeted tool for fat metabolism research without systemic anabolic effects.

Full-length human growth hormone is a 191-amino-acid single-chain protein that acts through a complex two-site receptor binding mechanism. When hGH binds its receptor, it triggers a cascade involving JAK2 and STAT5 phosphorylation, leading to IGF-1 secretion from the liver, protein synthesis in muscle, and a range of metabolic effects including reduced glucose uptake and elevated blood lipids.

AOD-9604 carries none of that signaling baggage. Because it represents only the C-terminal 15 residues, it lacks both the Site 1 and Site 2 binding surfaces required for GH receptor dimerization. No receptor dimerization means no JAK2 activation. No JAK2 activation means no STAT5 phosphorylation and no downstream IGF-1 production. The anabolic and diabetogenic effects associated with GH excess simply do not appear in AOD-9604 assay systems.

This is a meaningful distinction for research design. A study exploring obesity-related adipose dysfunction needs a lipolytic stimulus that does not simultaneously create insulin resistance or alter cell proliferation rates. AOD-9604 provides that stimulus. A researcher using full hGH for the same purpose would need to control for at least four or five additional variables, complicating both the protocol and the interpretation.

The peptide also differs pharmacokinetically from hGH. Full-length growth hormone has a half-life of 15 to 20 minutes after intravenous delivery in most animal models. The smaller fragment clears more quickly in many in vitro systems, a factor that experimental teams need to factor into dosing intervals and time-course sampling plans.

In summary: hGH is a multi-function hormone. AOD-9604 is a single-function fragment. For researchers who need clean data on lipolysis, that narrower profile is an advantage, not a limitation.

Laboratory Handling and Storage Protocols

AOD-9604 supplied as a lyophilized powder should be stored at -20 degrees Celsius (or colder) in a dry, dark environment. Reconstitute with sterile bacteriostatic water or an appropriate aqueous buffer. Avoid repeated freeze-thaw cycles. Prepared solutions remain stable for up to 14 days at 4 degrees Celsius when stored correctly.

Proper handling starts before the vial is even opened. Lyophilized peptide powders are hygroscopic, meaning they absorb moisture from the air. A vial of AOD-9604 should be allowed to reach room temperature before opening, preventing condensation from entering the powder. Even a few seconds of unnecessary exposure to humid lab air can degrade a batch over time.

Storage at -20 degrees Celsius is standard for long-term stability of the lyophilized form. Some facilities opt for -80 degrees Celsius for archival storage, which provides additional margin against cumulative thermal stress. Avoid storing near the door of a freezer where temperature fluctuates with each open-close cycle. A dedicated inner shelf position is preferable.

Reconstitution should use sterile bacteriostatic water or a compatible aqueous buffer chosen to match downstream assay requirements. Adding acetonitrile or DMSO is generally not necessary and may complicate downstream cell-based assays. Introduce the reconstitution solvent gently down the side of the vial, then allow dissolution without vigorous vortexing. AOD-9604 dissolves well under gentle agitation.

PeptideValidation.com provides AOD-9604 in a 2 mg lyophilized format, which gives laboratory teams flexibility. A single vial can support multiple experimental runs when aliquots are prepared and frozen individually at the point of reconstitution. This avoids repeated freeze-thaw cycling of the same stock solution, which degrades the disulfide bond over time and reduces assay reproducibility.

Always verify peptide purity by HPLC and confirm identity by mass spectrometry before incorporating any lot into a formal study. Research-grade suppliers should provide a certificate of analysis (CoA) with each batch. Cross-referencing the observed molecular ion at approximately 1817 Da against the theoretical value is a quick, reliable identity check that takes under 10 minutes on a standard LC-MS system.

AOD-9604 vs. Related Peptide Fragments: A Comparison

AOD-9604 is a 15-amino-acid C-terminal hGH fragment focused on lipolysis. Compared to other metabolic peptides like CJC-1295, Ipamorelin, and Fragment 176-191, it occupies a distinct mechanistic niche: it stimulates fat breakdown via beta-3 adrenergic pathways rather than elevating GH secretion or binding ghrelin receptors.

Researchers working in the metabolic peptide space often need to choose between several related compounds depending on the signaling pathway they want to probe. AOD-9604 sits in a specific niche, direct lipolytic action via adipocyte receptors, that is distinct from peptides that work by stimulating endogenous GH release or mimicking ghrelin.

CJC-1295 is a GHRH analogue that extends the half-life of endogenous growth hormone-releasing hormone, leading to elevated GH pulse amplitude. It affects GH secretion upstream, not lipolysis directly. Ipamorelin is a selective GH secretagogue acting on the ghrelin receptor (GHSR-1a); it raises GH levels without significantly affecting cortisol or prolactin. Both peptides drive fat loss indirectly by raising systemic GH, whereas AOD-9604 bypasses GH secretion entirely.

Fragment 176-191 is worth noting separately. Some literature uses 'Fragment 176-191' and 'AOD-9604' interchangeably, but there is a subtle sequence difference. Researchers should confirm sequence and structure from their supplier's CoA before assuming equivalence between products sourced from different vendors.

Tesamorelin is a GHRH analogue approved by the FDA for visceral fat reduction in HIV-associated lipodystrophy. It operates through GH release and subsequent IGF-1 elevation, a fundamentally different pathway from AOD-9604. Its approved clinical status makes it useful as a pharmacological reference point in some in vitro benchmarking studies.

The comparison table in the following section summarizes the mechanistic and structural differences across these commonly studied peptides. For experimental teams selecting a compound for a specific assay, mechanism of action should drive the decision, not general labeling as a 'fat-loss peptide.'

Research Design Considerations

When designing an AOD-9604 study, researchers should control for: (1) peptide purity and lot consistency, (2) reducing agent presence in buffers (which disrupts the disulfide bond), (3) beta-3 adrenergic receptor expression levels in the chosen cell line, (4) baseline metabolic rate in animal models, and (5) time-course sampling intervals matched to expected peptide half-life.

Good experimental design with AOD-9604 starts with understanding which variables the compound can and cannot control. The peptide provides a selective lipolytic stimulus, but its effects depend heavily on the receptor expression profile of the cell or tissue model in question. A cell line with low beta-3 adrenergic receptor expression will give blunted responses. Before running a full dose-response study, it is worth confirming receptor expression levels by qPCR or Western blot.

Buffer chemistry is a frequent source of avoidable error. As noted earlier, DTT and beta-mercaptoethanol cleave the disulfide bond that gives AOD-9604 its active conformation. If your upstream protocol or lysis buffer contains these agents, the peptide will be inactive by the time it reaches the binding site. Use HEPES- or PBS-based buffers without reducing agents for assays that include this peptide.

Animal model selection matters for translational relevance. Diet-induced obese (DIO) mouse models and Zucker fatty rats have both been used in published AOD-9604 studies. DIO models more closely reflect human metabolic syndrome conditions. Genetic models like ob/ob mice provide a different obesity etiology, which may produce divergent results. Define the model based on the specific research question.

Sampling intervals should account for peptide clearance. AOD-9604 is a small peptide (approximately 1817 Da) and clears from plasma relatively quickly compared to larger proteins. If measuring circulating fatty acid levels as a readout of lipolytic activity, sampling at 15, 30, 60, and 120 minutes post-administration captures the response curve adequately in most rodent protocols.

Finally, include both positive and negative controls in each run. A known beta-3 agonist such as CL-316,243 serves as a useful positive control for the lipolytic pathway. Vehicle-only controls establish baseline. This is basic practice, but it is especially important when working with a compound like AOD-9604 where the research literature spans two decades and involves heterogeneous protocols across different laboratories.

Regulatory and Compliance Context

AOD-9604 is not approved by the FDA or EMA as a therapeutic drug for human use as of 2026. It is classified as a research chemical in most jurisdictions and may only be legally purchased and used for in vitro or preclinical laboratory research by qualified institutions. Researchers should verify local regulations before procurement.

Metabolic Pharmaceuticals advanced AOD-9604 through Phase IIb clinical trials in the 2000s under the designation AOD9604, and the compound was also assigned FDA Orphan Drug status for a time during development. However, no regulatory body has approved AOD-9604 as a licensed therapeutic for human use as of July 2026. Phase IIb results were not sufficient to justify moving to Phase III for the primary obesity indication.

In the United States, research peptides like AOD-9604 occupy a regulatory gray area. The FDA has issued guidance documents making clear that peptides sold explicitly or implicitly for human consumption, self-administration, or compounding violate federal law without an IND or NDA. Research suppliers operating legally sell exclusively to qualified researchers and institutions under the explicit understanding that the material is for laboratory use only.

In Australia, where much of the foundational AOD-9604 research was conducted, the Therapeutic Goods Administration (TGA) regulates peptides under its scheduling framework. WADA (the World Anti-Doping Agency) added AOD-9604 to its prohibited list for competitive sport as far back as 2013, citing its potential performance-enhancing effects on body composition. Researchers affiliated with sports science institutions should be aware of this context even when conducting purely in vitro work.

For institutions in the EU, the European Medicines Agency's guidelines on peptide medicinal products apply if the research transitions toward clinical development. At the preclinical stage, GLP (Good Laboratory Practice) compliance frameworks govern how such compounds are handled, documented, and reported.

PeptideValidation.com provides AOD-9604 explicitly for research use only and requires that purchasing institutions confirm their research context. This compliance posture protects both the supplier and the researcher. Maintaining clear documentation of intended use, storage conditions, and disposal records is standard practice and protects research teams during institutional audits.

Comparison

Frequently asked questions

Sources

• Heffernan et al., Journal of Endocrinology (2001), Cited in the Key Research Findings section to support preclinical rodent data showing AOD-9604 reduced body fat mass without affecting lean body mass, blood glucose, or insulin levels in obese mouse models.
• World Anti-Doping Agency (WADA) Prohibited List, Cited in the Regulatory and Compliance Context section to confirm that WADA added AOD-9604 to its Prohibited List in 2013 under peptide hormones and related substances, relevant for researchers in sports science institutions.

Related guides from this series

• Understanding the AOD-9604 Peptide: A 2026 Overview
• AOD-9604 Peptide vs HGH Fragment: Key Differences
• The Science of AOD-9604 Peptide: What Research Shows
• AOD-9604 Peptide Buyer's Guide: What Researchers Need